The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Standard

The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. / Bayoumi, Ali; Grønbæk, Henning; George, Jacob; Eslam, Mohammed.

I: Trends in Genetics, Bind 36, Nr. 6, 06.2020, s. 429-441.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bayoumi, Ali ; Grønbæk, Henning ; George, Jacob ; Eslam, Mohammed. / The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. I: Trends in Genetics. 2020 ; Bind 36, Nr. 6. s. 429-441.

Bibtex

@article{8b993cd1841a44fa95c811b056b19cfd,
title = "The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease",
abstract = "Despite decades of research, effective therapies for metabolic (dysfunction)-associated fatty liver disease (MAFLD) are lacking. An increasing body of evidence suggests that epigenetic dysregulation is frequent in MAFLD, and orchestrates many aspects of its development and progression. Furthermore, the high plasticity of epigenetic modifications in response to environmental cues renders epigenetics a novel area for therapeutic drug discovery. Over recent years, several epigenetics-based drugs and diagnostic biomarkers have entered clinical development and/or obtained regulatory approval. Here, we review recent advances in our understanding of epigenetic regulation and programming during MAFLD, including DNA methylation, histone modifications, chromatin remodelling, transcriptional control, and noncoding (nc)RNAs. We also discuss the potential translational implications and challenges of epigenetics in the context of MAFLD.",
keywords = "DNA methylation, epigenetics, fibrosis, MAFLD, NAFLD",
author = "Ali Bayoumi and Henning Gr{\o}nb{\ae}k and Jacob George and Mohammed Eslam",
year = "2020",
month = jun,
doi = "10.1016/j.tig.2020.03.003",
language = "English",
volume = "36",
pages = "429--441",
journal = "Trends in Genetics",
issn = "0168-9525",
publisher = "Elsevier Ltd. * Trends Journals",
number = "6",

}

RIS

TY - JOUR

T1 - The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease

AU - Bayoumi, Ali

AU - Grønbæk, Henning

AU - George, Jacob

AU - Eslam, Mohammed

PY - 2020/6

Y1 - 2020/6

N2 - Despite decades of research, effective therapies for metabolic (dysfunction)-associated fatty liver disease (MAFLD) are lacking. An increasing body of evidence suggests that epigenetic dysregulation is frequent in MAFLD, and orchestrates many aspects of its development and progression. Furthermore, the high plasticity of epigenetic modifications in response to environmental cues renders epigenetics a novel area for therapeutic drug discovery. Over recent years, several epigenetics-based drugs and diagnostic biomarkers have entered clinical development and/or obtained regulatory approval. Here, we review recent advances in our understanding of epigenetic regulation and programming during MAFLD, including DNA methylation, histone modifications, chromatin remodelling, transcriptional control, and noncoding (nc)RNAs. We also discuss the potential translational implications and challenges of epigenetics in the context of MAFLD.

AB - Despite decades of research, effective therapies for metabolic (dysfunction)-associated fatty liver disease (MAFLD) are lacking. An increasing body of evidence suggests that epigenetic dysregulation is frequent in MAFLD, and orchestrates many aspects of its development and progression. Furthermore, the high plasticity of epigenetic modifications in response to environmental cues renders epigenetics a novel area for therapeutic drug discovery. Over recent years, several epigenetics-based drugs and diagnostic biomarkers have entered clinical development and/or obtained regulatory approval. Here, we review recent advances in our understanding of epigenetic regulation and programming during MAFLD, including DNA methylation, histone modifications, chromatin remodelling, transcriptional control, and noncoding (nc)RNAs. We also discuss the potential translational implications and challenges of epigenetics in the context of MAFLD.

KW - DNA methylation

KW - epigenetics

KW - fibrosis

KW - MAFLD

KW - NAFLD

UR - http://www.scopus.com/inward/record.url?scp=85082521229&partnerID=8YFLogxK

U2 - 10.1016/j.tig.2020.03.003

DO - 10.1016/j.tig.2020.03.003

M3 - Review

C2 - 32396836

AN - SCOPUS:85082521229

VL - 36

SP - 429

EP - 441

JO - Trends in Genetics

JF - Trends in Genetics

SN - 0168-9525

IS - 6

ER -